Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A novel CD38-targeted immuno-PET tracer is showing promise in spotting multiple myeloma that slips past standard imaging. In a phase II trial, the new tracer identified more disease sites than conventional FDG PET/CT in 28% of patients — and the two scans caught different lesions in others. Researchers say the tools work best as complements, not replacements.
A new imaging tool may help oncologists find multiple myeloma that standard scans routinely miss. A phase II trial published in Radiology tested a CD38-targeted immuno-PET tracer — 89Zr-DFO-daratumumab — against the standard-of-care FDG PET/CT in 60 patients with confirmed multiple myeloma. While overall detection rates were similar (43% vs. 47%), the two scans caught different lesions, suggesting they work best together rather than as substitutes.
The new tracer is built on daratumumab (Darzalex), an actual myeloma treatment, meaning a positive scan could also hint at drug effectiveness. Researchers are optimistic that pairing immuno-PET with liquid biopsies could further improve early disease detection.
By the Numbers:
Why it matters: Multiple myeloma is notoriously hard to fully stage with existing tools. This complementary imaging approach could help ensure no disease is left behind — a critical step toward achieving better outcomes for patients.
